Peptide Therapy Protocols for Medical Practices: A 2026 Clinical Reference

Peptide therapy has moved from the fringes of integrative medicine into mainstream outpatient practice. Practices offering GLP-1 programs are increasingly adding peptides as complementary protocols — for tissue repair, growth hormone optimization, sexual health, and longevity. The demand is real, and the clinical rationale is growing.

This reference covers the six most requested peptides in outpatient medicine, with evidence-informed protocols, dosing ranges, and the compliance framework every practice needs to understand before ordering.

Research Use Only peptides are available to licensed medical practices through compliant suppliers like MedClinic Partners. The RUO designation means:

• The compound has not completed the FDA approval process for a specific therapeutic indication
• It may be used in IRB-enrolled research programs with appropriate patient consent and documentation
• The practice bears responsibility for informed consent, documentation, and compliance with state medical board guidelines
• The supplier must provide certificates of analysis (COA) and third-party testing documentation

Practices that are IRB-enrolled have the strongest compliance posture for peptide programs. MedClinic Partners facilitates IRB enrollment for qualifying practices.

Mechanism: BPC-157 is a pentadecapeptide derived from a protective protein found in gastric juice. It promotes angiogenesis, upregulates growth hormone receptors, and has demonstrated anti-inflammatory and tissue-protective effects in preclinical models.

Primary applications:

• Musculoskeletal injury recovery (tendon, ligament, muscle)
• GI tract healing and permeability
• Neuroprotection and CNS recovery
• Post-surgical healing support

Dosing range (subcutaneous or intramuscular):

• Standard: 200–400 mcg once or twice daily
• Acute injury: 500 mcg twice daily for 2–4 weeks, then taper
• Maintenance: 200 mcg daily

Administration: Subcutaneous injection at or near the site of injury is commonly used for musculoskeletal applications. Systemic subcutaneous injection is used for GI and systemic applications.

Cycle length: 4–12 weeks depending on indication. No established maximum duration in human research.

Safety profile: BPC-157 has a favorable preclinical safety profile with no reported serious adverse events in human use at standard doses. GI tolerance is generally excellent.

Mechanism: TB-500 is a synthetic version of Thymosin Beta-4, a naturally occurring peptide involved in actin regulation, cell migration, and tissue repair. It promotes angiogenesis, reduces inflammation, and accelerates wound healing.

Primary applications:

• Chronic tendon and ligament injuries
• Cardiac tissue repair (emerging research)
• Wound healing and scar reduction
• Systemic anti-inflammatory support

Dosing range (subcutaneous):

• Loading phase: 4–8 mg weekly for 4–6 weeks
• Maintenance: 2–2.5 mg biweekly

Administration: Subcutaneous injection, typically in the abdomen or thigh. Not site-specific — systemic distribution is the mechanism.

Cycle length: 4–6 week loading phase followed by maintenance as needed.

Combination use: BPC-157 and TB-500 are frequently used together ("BPC/TB stack") for musculoskeletal recovery. The mechanisms are complementary — BPC-157 promotes local tissue repair while TB-500 provides systemic anti-inflammatory and angiogenic support.

Mechanism: CJC-1295 is a GHRH (growth hormone-releasing hormone) analogue that stimulates the pituitary to release growth hormone. Ipamorelin is a selective GHRP (growth hormone-releasing peptide) that amplifies the GH pulse without significantly raising cortisol or prolactin. Used together, they produce a synergistic, physiologic GH pulse.

Primary applications:

• Growth hormone optimization in adults with age-related GH decline
• Body composition improvement (lean mass, fat reduction)
• Sleep quality and recovery
• Anti-aging and longevity protocols

Dosing range (subcutaneous):

• CJC-1295 (without DAC): 100–200 mcg per injection
• Ipamorelin: 100–300 mcg per injection
• Typically dosed together, 1–3 times daily
• Most common protocol: once daily at bedtime (to mimic natural GH pulse)

Administration: Subcutaneous injection, abdomen preferred. Administer on an empty stomach or 2+ hours after a meal for optimal GH response.

Cycle length: 3–6 months, with 1–2 month breaks. Some patients use continuously under monitoring.

Monitoring: IGF-1 levels at baseline and 6–8 weeks into protocol. Adjust dosing to keep IGF-1 in the upper-normal range for age.

Mechanism: PT-141 is a melanocortin receptor agonist that acts centrally (in the CNS) to increase sexual arousal and desire. Unlike PDE5 inhibitors (sildenafil, tadalafil), PT-141 does not act on the vascular system — it works through the hypothalamus and limbic system.

Primary applications:

• Hypoactive sexual desire disorder (HSDD) in women
• Erectile dysfunction, particularly in cases where PDE5 inhibitors are insufficient or contraindicated
• Sexual dysfunction associated with hormonal changes (menopause, andropause)

Dosing range (subcutaneous):

• Standard: 1–2 mg subcutaneous injection 45–60 minutes before sexual activity
• Start low: 0.5–1 mg for first use to assess tolerance
• Maximum: 2 mg per dose; do not use more than once per 72 hours

Administration: Subcutaneous injection, abdomen or thigh. Onset 45–60 minutes, duration 6–12 hours.

Side effects: Nausea (most common, usually mild), flushing, transient blood pressure changes. Nausea is dose-dependent and typically resolves within 1–2 hours.

Note: PT-141 (bremelanotide) is FDA-approved as Vyleesi for HSDD in premenopausal women. The compounded version is available through 503A channels for off-label use in men and postmenopausal women.

Mechanism: Sermorelin is a synthetic analogue of the first 29 amino acids of endogenous GHRH. It stimulates the pituitary gland to produce and secrete growth hormone in a physiologic, pulsatile manner — unlike exogenous HGH, which suppresses the pituitary's own production.

Primary applications:

• Adult growth hormone deficiency
• Age-related GH decline and body composition changes
• Sleep quality improvement
• Recovery and anti-aging protocols

Dosing range (subcutaneous):

• Standard: 200–500 mcg at bedtime
• Diagnostic use: 1 mcg/kg IV (GHRH stimulation test)

Administration: Subcutaneous injection at bedtime on an empty stomach. Bedtime dosing aligns with the natural nocturnal GH pulse.

Cycle length: Continuous use is common under IGF-1 monitoring. Some protocols use 5 days on / 2 days off.

Comparison to CJC-1295/Ipamorelin: Sermorelin has a shorter half-life and produces a more physiologic GH pulse. CJC-1295/Ipamorelin produces a stronger, more sustained GH release. For patients new to GH optimization, Sermorelin is often the preferred starting point.

Mechanism: Epithalon is a synthetic tetrapeptide (Ala-Glu-Asp-Gly) derived from the pineal gland peptide Epithalamin. It activates telomerase, the enzyme responsible for maintaining telomere length, and has demonstrated antioxidant, anti-tumor, and circadian rhythm-regulating effects in preclinical research.

Primary applications:

• Longevity and anti-aging protocols
• Telomere maintenance
• Sleep regulation and circadian rhythm support
• Antioxidant and cellular protection

Dosing range:

• Subcutaneous: 5–10 mg daily for 10–20 days, 1–2 cycles per year
• Intranasal: 10–20 mg daily (less common, lower bioavailability)

Administration: Subcutaneous injection, abdomen. Typically administered in defined cycles rather than continuously.

Cycle protocols:

• Short cycle: 10 mg/day × 10 days, twice yearly
• Extended cycle: 5 mg/day × 20 days, once yearly

Safety profile: Epithalon has a favorable safety profile in available research. No significant adverse events reported at standard doses.

IRB enrollment provides the research framework for offering RUO peptides. MedClinic Partners facilitates enrollment for qualifying practices.

Every patient receiving RUO peptides must sign an informed consent document that explains the RUO status, the available research, and the absence of FDA approval for the specific indication.

Your peptide supplier must provide:

• Certificate of Analysis (COA) for each lot
• Third-party testing documentation (HPLC purity, endotoxin testing)
• Confirmation of USA-manufactured API
• 503A or 503B registration

Establish baseline labs appropriate to the protocol (IGF-1 for GH peptides, hormone panels for sexual health peptides) and schedule follow-up monitoring at 6–8 weeks.

MedClinic Partners supplies all six peptides covered in this guide through IRB-enrolled, USA-manufactured, cGMP-compliant channels. Licensed providers can access the full peptide catalog through our NPI-verified portal with next-day refrigerated delivery.